Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Olalekan O. Oluwole, Rongzhe Liu, Ibrahim Diakite, Chaoling Feng, Anik Patel, Iman Nourhussein, Julia Thornton Snider & Frederick L. Locke. (2022) Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Journal of Medical Economics 25:1, pages 541-551.
Read now
Read now
H. El Sayed, S. Shalaby, M. R. E. Abdel-Halim, D. M. Aboelfadl & N. Samir. (2021) Efficacy of doxycycline in the treatment of early stages of mycosis fungoides: a randomized controlled trial. Journal of Dermatological Treatment 32:4, pages 424-431.
Read now
Read now
Rongzhe Liu, Olalekan O. Oluwole, Ibrahim Diakite, Marc F. Botteman, Julia Thornton Snider & Frederick L. Locke. (2021) Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. Journal of Medical Economics 24:1, pages 458-468.
Read now
Read now
Julie M. Vose, Jonathan W. Friedberg, Edmund K. Waller, Bruce D. Cheson, Vasthala Juvvigunta, Holger Fritsch, Claude Petit, Gerd Munzert & Anas Younes. (2013) The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leukemia & Lymphoma 54:4, pages 708-713.
Read now
Read now
Kyoko Hanzawa, Shuji Momose, Morihiro Higashi, Michihide Tokuhira, Reiko Watanabe, Kazunori Kajino, Okio Hino, Shinji Itoyama, Masahiro Kizaki & Jun-Ichi Tamaru. (2010) Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era. Leukemia & Lymphoma 51:11, pages 2054-2062.
Read now
Read now
Articles from other publishers (17)
Marta Sureda-Gómez, Patricia Balsas, Marta-Leonor Rodríguez, Ferran Nadeu, Anna De Bolòs, Álvaro Eguileor, Marta Kulis, Giancarlo Castellano, Cristina López, Eva Giné, Santiago Demajo, Pedro Jares, José I. Martín-Subero, Silvia Beà, Elias Campo & Virginia Amador. (2022) Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma. Leukemia 37:2, pages 408-421.
Crossref
Crossref
Jinjin Wang, Hui Zhou, Mingchun Mu, Ailin Zhao, Zhaolun Cai, Linfeng Li, Mengyao Wang & Ting Niu. (2022) Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials. Frontiers in Immunology 13.
Crossref
Crossref
Shuping Xie, Zhong Yu, Aozi Feng, Shuai Zheng, Yunmei Li, You Zeng & Jun Lyu. (2022) Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method. Frontiers in Oncology 12.
Crossref
Crossref
Colby S. Shemesh, Priya Agarwal, Tong Lu, Calvin Lee, Randall C. Dere, Xiaobin Li, Chunze Li, Jin Y. Jin, Sandhya Girish, Dale Miles & Dan Lu. (2020) Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology 85:5, pages 831-842.
Crossref
Crossref
Sudjit Luanpitpong, Montira Janan, Kanjana Thumanu, Jirarat Poohadsuan, Napachai Rodboon, Phatchanat Klaihmon & Surapol Issaragrisil. (2019) Deciphering the Elevated Lipid via CD36 in Mantle Cell Lymphoma with Bortezomib Resistance Using Synchrotron-Based Fourier Transform Infrared Spectroscopy of Single Cells. Cancers 11:4, pages 576.
Crossref
Crossref
Sudjit Luanpitpong, Jirarat Poohadsuan, Parinya Samart, Chayanin Kiratipaiboon, Yon Rojanasakul & Surapol Issaragrisil. (2018) Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1864:11, pages 3739-3753.
Crossref
Crossref
Carolina V. Alexander-Savino, Matthew S. Hayden, Christopher Richardson, Jiyong Zhao & Brian Poligone. (2016) Doxycycline is an NF-κB inhibitor that induces apoptotic cell death in malignant T-cells. Oncotarget 7:46, pages 75954-75967.
Crossref
Crossref
David Belada, Pencho Georgiev, Shaker Dakhil, Lowell F Inhorn, David Andorsky, J Thaddeus Beck, Donald Quick, Ruth Pettengell, Robert Daly, James P Dean, Mariya Pavlyuk, Nelly Failloux & Kai Hübel. (2016) Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future Oncology 12:15, pages 1759-1768.
Crossref
Crossref
Lavleen Singh, Renu Madan, Rony Benson & Goura Kishore Rath. (2014) Primary Non-Hodgkins Lymphoma of Uterine Cervix: A Case Report of Two Patients. The Journal of Obstetrics and Gynecology of India 66:2, pages 125-127.
Crossref
Crossref
K. David Li & Mohamed E. Salama. (2016) Therapy Effect. Surgical Pathology Clinics 9:1, pages 177-187.
Crossref
Crossref
Rohit Mathur, Lalit Sehgal, Frank K. Braun, Zuzana Berkova, Jorge Romaguerra, Michael Wang, M. Alma Rodriguez, Luis Fayad, Sattva S. Neelapu & Felipe Samaniego. (2015) Targeting Wnt pathway in mantle cell lymphoma-initiating cells. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
XUEDE LIN, XI SHI, WUCHA ZENG, MIN ZHENG & LIMING HUANG. (2014) Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin’s lymphoma patients with a poor performance status or comorbidity. Oncology Letters 8:5, pages 2012-2016.
Crossref
Crossref
Steve A Maxwell & Seyed Mousavi-Fard. (2013) Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance. Experimental Biology and Medicine 238:9, pages 971-990.
Crossref
Crossref
Jan-Henrik Mikesch, Mareike Kuhlmann, Angela Demant, Utz Krug, Gabriela B. Thoennissen, Eva Schmidt, Torsten Kessler, Christoph Schliemann, Michele Pohlen, Michael Mohr, Georg Evers, Gabriele Köhler, Johannes Wessling, Rolf Mesters, Carsten Müller-Tidow, Wolfgang E. Berdel & Nils H. Thoennissen. (2013) DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Annals of Hematology 92:8, pages 1041-1048.
Crossref
Crossref
Anthony R. Mato, Tatyana Feldman & André Goy. (2012) Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside. The Oncologist 17:5, pages 694-707.
Crossref
Crossref
Yihu Zheng, Kang Yu, Jimei Du, Lei Jiang, Shenghui Zhang, Yixiang Han, Panpan Yu & Yingxia Tan. (2010) Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells. Journal of Experimental & Clinical Cancer Research 29:1.
Crossref
Crossref
Agustin Avilés, Natividad Neri, Judith Huerta-Guzmán & María de Jesús Nambo. (2010) ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 10:2, pages 125-128.
Crossref
Crossref